Ikarian Capital’s Blueprint Medicines BPMC Stock Holding History

Ikarian Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-120,000	Closed	-$11.7M	–	228
2021 Q1	$11.7M	Hold	120,000	–	–	0.39%	58
2020 Q4	$13.5M	Buy	+120,000	New	+$12.6M	0.59%	39
2020 Q3	–	Sell	-400,000	Closed	-$31.2M	–	186
2020 Q2	$31.2M	Buy	400,000 +334,000	+506%	+$22.6M	2.48%	2
2020 Q1	$3.86M	Buy	+66,000	New	+$4.25M	0.29%	72

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's BPMC Position: Q2 2025 in Review

Ikarian Capital sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 113,904 shares — an estimated $10.1M sold.

Ikarian Capital first reported a position in BPMC in Q2 2020 and held it in 4 quarters. The position peaked at $15.7M in Q2 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Ikarian Capital reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 113,904 Blueprint Medicines shares in Q2 2025, an estimated $10.1M.
Ikarian Capital first reported a position in Blueprint Medicines in Q2 2020 and held it in 4 quarters.
Ikarian Capital's Blueprint Medicines position peaked at $15.7M in Q2 2020.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.